Patents by Inventor Annie L. Lennek

Annie L. Lennek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of RAS GTPase
    Patent number: 11945803
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: April 2, 2024
    Assignee: Tosk, Inc.
    Inventors: Annie L. Lennek, Stephen D. Yanofsky, Brian D. Frenzel, Solomon B. Ungashe, William A. Garland, Philip Liaw
  • Modulators of RAS GTPase
    Publication number: 20220227740
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 21, 2022
    Inventors: Solomon B. Ungashe, William A. Garland, Stephen D. Yanofsky, Brian D. Frenzel, Philip Liaw, Annie L. Lennek
  • Pyrazolopyrimidine modulators of RAS GTPase
    Patent number: 11390626
    Abstract: Pyrazolopyrimidine RAS modulating compounds and methods of using the same are provided. The pyrazolopyrimidine compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: July 19, 2022
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Solomon B. Ungashe, Stephen D. Yanofsky, Philip Liaw, Annie L. Lennek
  • Modulators of RAS GTPase
    Publication number: 20210261532
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: August 6, 2019
    Publication date: August 26, 2021
    Inventors: Annie L. Lennek, Stephen D. Yanofsky, Brian D. Frenzel, Solomon B. Ungashe, William A. Garland, Philip Liaw
  • Pyrazolopyrimidine Modulators of RAS GTPase
    Publication number: 20200239479
    Abstract: Pyrazolopyrimidine RAS modulating compounds and methods of using the same are provided. The pyrazolopyrimidine compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: January 28, 2020
    Publication date: July 30, 2020
    Inventors: William A. Garland, Solomon B. Ungashe, Stephen D. Yanofsky, Philip Liaw, Annie L. Lennek